Exact Mass: 245.17795479999998

Exact Mass Matches: 245.17795479999998

Found 317 metabolites which its exact mass value is equals to given mass value 245.17795479999998, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dezocine

5,11-Methanobenzocyclodecen-3-ol, 13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-, (5alpha,11alpha,13S*)

C16H23NO (245.17795479999998)


Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics N - Nervous system > N02 - Analgesics > N02A - Opioids

   

beta-Alanyl-L-arginine

(2S)-2-[(3-amino-1-hydroxypropylidene)amino]-5-carbamimidamidopentanoic acid

C9H19N5O3 (245.1487824)


This compound belongs to the family of Hybrid Peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta).

   
   

Tropacocain

3beta-Benzoyloxytropane

C15H19NO2 (245.1415714)


   

Isovalerylcarnitine

3-Methylbutyrylcarnitine, (+-)-isomer

C12H23NO4 (245.16269979999998)


Isovalerylcarnitine is the phenotypic abnormality in isovaleric acidemia (OMIM 243500) resulting from an accumulation of isovaleric acid, which is toxic to the central nervous system. Isovaleric acidemia is an autosomal recessive inborn error of leucine metabolism caused by a deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (EC 1.3.99.10) resulting in the accumulation of derivatives of isovaleryl-CoA. It was the first organic acidemia recognized in humans and can cause significant morbidity and mortality. Early diagnosis and treatment with a protein restricted diet and supplementation with carnitine and glycine are effective in promoting normal development in severely affected individuals. An alternative pathway through glycine-N-acylase (EC 2.3.1.13) allows detoxification by producing isovalerylglycine, which is excreted. Thus, isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition (PMID: 16602101). Moreover, isovalerylcarnitine is found to be associated with celiac disease and very long-chain acyl-CoA dehydrogenase deficiency (VLCAD), which are also inborn errors of metabolism. Isovalerylcarnitine is the phenotypic abnormality in isovaleric acidemia (OMIM 243500) resulting from an accumulation of isovaleric acid, which is toxic to the central nervous system. Isovaleric acidemia is an autosomal recessive inborn error of leucine metabolism caused by a deficiency of the mitochondrial enzyme isovaleryl-CoA dehydrogenase (EC 1.3.99.10) resulting in the accumulation of derivatives of isovaleryl-CoA. It was the first organic acidemia recognized in humans and can cause significant morbidity and mortality. Early diagnosis and treatment with a protein restricted diet and supplementation with carnitine and glycine are effective in promoting normal development in severely affected individuals. An alternative pathway through glycine-N-acylase (EC 2.3.1.13) allows detoxification by producing isovalerylglycine, which is excreted. Thus, isovalerylcarnitine and isovalerylglycine are the hallmarks of this disorder in plasma and urine, respectively, and are elevated regardless of a patients metabolic condition. (PMID: 16602101) [HMDB] Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis[1][2][3].

   

Benzoyltropein

3alpha-Benzoyloxytropane

C15H19NO2 (245.1415714)


   

Alanylarginine

(2S)-2-{[(2S)-2-amino-1-hydroxypropylidene]amino}-5-carbamimidamidopentanoate

C9H19N5O3 (245.1487824)


Alanylarginine is a dipeptide composed of alanine and arginine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Glutaminylvaline

(2S)-2-{[(2S)-2-amino-1-hydroxy-4-(C-hydroxycarbonimidoyl)butylidene]amino}-3-methylbutanoate

C10H19N3O4 (245.13754939999998)


Glutaminylvaline is a dipeptide composed of glutamine and valine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Asparaginylisoleucine

(2S,3S)-2-{[(2S)-2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-3-methylpentanoate

C10H19N3O4 (245.13754939999998)


Asparaginylisoleucine is a dipeptide composed of asparagine and isoleucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Valyllysine

(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanoic acid

C11H23N3O3 (245.1739328)


Valyllysine is a dipeptide composed of valine and lysine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Lysylvaline

(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanoic acid

C11H23N3O3 (245.1739328)


Lysylvaline is a dipeptide composed of lysine and valine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Arginylalanine

(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]propanoic acid

C9H19N5O3 (245.1487824)


Arginylalanine is a dipeptide composed of arginine and alanine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

2-Methylbutyroylcarnitine

L-2-Methylbutyrate (3-carboxy-2-hydroxypropyl)trimethyl-hydroxide ammonium inner salt

C12H23NO4 (245.1626998)


2-Methylbutyroylcarnitine is an acylcarnitine. More specifically, it is an 2-methylbutanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Methylbutyroylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine 2-methylbutyroylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. In particular 2-methylbutyroylcarnitine is elevated in the blood or plasma of individuals with exudative age-related macular degeneration (PMID: 32120889), type 2 Diabetes Mellitus (PMID: 31782507, PMID: 20111019), obesity (PMID: 20111019), acute cerebral infarction (PMID: 29265114), diastolic heart failure (PMID: 26010610), systolic heart failure (PMID: 26010610). It is also decreased in the blood or plasma of individuals with pregnancy (PMID: 24704061 - in serum of pregnant women with fetus with CHD). Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. Usually not detected in normal individuals, the elevation of 2-methylbutyrylcarnitine suggests a deficiency of a dehydrogenase specific for isobutyryl-CoA, important in the differential diagnosis of Branched Chain Organic Acidurias by Analysis of Urinary Organic Acids and Acylcarnitines in Plasma or Dried Blood Spots (The Metabolic and Molecular Bases of Inherited Disease, Chapter 93) [HMDB]

   

Valylglutamine

(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-carbamoylbutanoic acid

C10H19N3O4 (245.13754939999998)


Valylglutamine is a dipeptide composed of valine and glutamine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Isoleucyl-Asparagine

2-[(2-Amino-1-hydroxy-3-methylpentylidene)amino]-3-(C-hydroxycarbonimidoyl)propanoate

C10H19N3O4 (245.13754939999998)


Isoleucyl-Asparagine is a dipeptide composed of isoleucine and asparagine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Asparaginyl-Leucine

2-{[2-amino-1-hydroxy-3-(C-hydroxycarbonimidoyl)propylidene]amino}-4-methylpentanoate

C10H19N3O4 (245.13754939999998)


Asparaginyl-Leucine is a dipeptide composed of asparagine and leucine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Leucyl-Asparagine

2-[(2-Amino-1-hydroxy-4-methylpentylidene)amino]-3-(C-hydroxycarbonimidoyl)propanoate

C10H19N3O4 (245.13754939999998)


Leucyl-Asparagine is a dipeptide composed of leucine and asparagine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Valyl-Gamma-glutamate

2-Amino-4-[(2-amino-3-methylbutanoyl)-C-hydroxycarbonimidoyl]butanoate

C10H19N3O4 (245.13754939999998)


Valyl-Gamma-glutamate is a dipeptide composed of valine and gamma-glutamate. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Pivaloylcarnitine

3-[(2,2-dimethylpropanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO4 (245.16269979999998)


Pivaloylcarnitine is an acylcarnitine. More specifically, it is an pivalic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Pivaloylcarnitine is therefore classified as a short chain AC. As a short-chain acylcarnitine Pivaloylcarnitine is a member of the most abundant group of carnitines in the body, comprising more than 50\\% of all acylcarnitines quantified in tissues and biofluids (PMID: 31920980). Some short-chain carnitines have been studied as supplements or treatments for a number of diseases, including neurological disorders and inborn errors of metabolism. Carnitine acetyltransferase (CrAT, EC:2.3.1.7) is responsible for the synthesis of all short-chain and short branched-chain acylcarnitines (PMID: 23485643). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

S-3-oxodecanoyl cysteamine

1-[(2-Aminoethyl)sulphanyl]decane-1,3-dione

C12H23NO2S (245.1449418)


S-3-oxodecanoyl cysteamine belongs to the family of Thioesters. These are compounds containing the ester derivative of thiocarboxylic acid,with the general structure R-S-CO-R (R,R=alkyl,aryl)

   

N-(3-(5,6,7,8-Tetrahydro-2-naphthyl)prop-2-enyl)acetohydroxamic acid

N-hydroxy-N-[3-(5,6,7,8-tetrahydronaphthalen-2-yl)prop-2-en-1-yl]acetamide

C15H19NO2 (245.1415714)


   

Bisnortilidin

Ethyl 2-amino-1-phenylcyclohex-3-ene-1-carboxylic acid

C15H19NO2 (245.1415714)


   

Pinacidil

N-cyano-N-(1,4-dihydropyridin-4-ylidene)-N-(3,3-dimethylbutan-2-yl)guanidine

C13H19N5 (245.16403739999998)


C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DG - Guanidine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D049990 - Membrane Transport Modulators

   

Centroton

1-(4-methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one

C16H23NO (245.17795479999998)


   

Ramifenazone

1,5-dimethyl-2-phenyl-4-[(propan-2-yl)amino]-2,3-dihydro-1H-pyrazol-3-one

C14H19N3O (245.15280439999998)


   

Tasimelteon

N-{[2-(2,3-dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanimidate

C15H19NO2 (245.1415714)


   
   
   
   
   

6-hydroxy-1H-indole-3-carbaldehyde

1-(6-Hydroxyhexyl)-1H-3-indolecarbaldehyde

C15H19NO2 (245.1415714)


   

alpha-5-C-(3-Hydroxybutyl)-hyacinthacine A2

(-)-alpha-5-C-(3-Hydroxybutyl)-hyacinthacine A2

C12H23NO4 (245.16269979999998)


   

Ramifenazone

Ramifenazone

C14H19N3O (245.15280439999998)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

   

tolperisone

tolperisone

C16H23NO (245.17795479999998)


M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain M - Musculo-skeletal system > M03 - Muscle relaxants > M03B - Muscle relaxants, centrally acting agents D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant D002491 - Central Nervous System Agents

   

Methyl 1-pentyl-1H-indole-3-carboxylate

Methyl 1-pentyl-1H-indole-3-carboxylate

C15H19NO2 (245.1415714)


   

PYROVALERONE

PYROVALERONE

C16H23NO (245.17795479999998)


D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

   

Pinacidil

Pinacidil

C13H19N5 (245.16403739999998)


C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DG - Guanidine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D049990 - Membrane Transport Modulators

   
   

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]acetamide

N-[2-(2,2-Dimethyl-2H-1-benzopyran-6-yl)ethyl]acetamide

C15H19NO2 (245.1415714)


   

(2E,4E,10E)-N-isobutyldodeca-2,4,10-trien-8-ynamide|2-Methylpropylamide 鈥樎?2E,4E,10E)-2,4,10-Dodecatrien-8-ynoic acid|dodeca-2E,4E,10E-trien-8-ynoic acid isobutylamide|N-isobutyldodeca-2E,4E,10E-triene-8-ynamide

(2E,4E,10E)-N-isobutyldodeca-2,4,10-trien-8-ynamide|2-Methylpropylamide 鈥樎?2E,4E,10E)-2,4,10-Dodecatrien-8-ynoic acid|dodeca-2E,4E,10E-trien-8-ynoic acid isobutylamide|N-isobutyldodeca-2E,4E,10E-triene-8-ynamide

C16H23NO (245.17795479999998)


   

2-Methylbutylamide-(Z)-2-Undecene-8,10-diynoic acid

2-Methylbutylamide-(Z)-2-Undecene-8,10-diynoic acid

C16H23NO (245.17795479999998)


   
   

(2S:3S:2R)-2-[Methyl-(alpha-hydroxy-isovaleryl)-amino]-3-methyl-valeriansaeure|N-Methyl-N-(D-alpha-hydroxy-isovaleryl)-L-isoleucin|N-methyl-N-(D-alpha-hydroxy-isovaleryl)-L-isoleucine

(2S:3S:2R)-2-[Methyl-(alpha-hydroxy-isovaleryl)-amino]-3-methyl-valeriansaeure|N-Methyl-N-(D-alpha-hydroxy-isovaleryl)-L-isoleucin|N-methyl-N-(D-alpha-hydroxy-isovaleryl)-L-isoleucine

C12H23NO4 (245.16269979999998)


   

1-(1H-Indol-3-yl)-2-hydroxy-4-methylhexan-3-one

1-(1H-Indol-3-yl)-2-hydroxy-4-methylhexan-3-one

C15H19NO2 (245.1415714)


   

1-Benzyl-2,2,6,6-tetramethylpiperidin-4-one

1-Benzyl-2,2,6,6-tetramethylpiperidin-4-one

C16H23NO (245.17795479999998)


   

3-phenylacetoxynortropane|nortropan-3-yl phenylacetate|Phenylessigsaeure-nortropinester

3-phenylacetoxynortropane|nortropan-3-yl phenylacetate|Phenylessigsaeure-nortropinester

C15H19NO2 (245.1415714)


   
   
   
   
   
   
   

(2E)-N-isobutyldodeca-2-ene-8,10-diynamide|(E)-N-isobutyl dodeca-2-ene-8,10-diynamide|(E)-N-isobutyldodeca-2-en-8,10-diynamide|(E)-N-isobutyldodeca-2-ene-8,10-diynamide|2-Methylpropylamide 鈥樎?E)-2-Dodecene-8,10-diynoic acid|Alk5|dodeca-2E-en-8,10-diynoic acid isobutylamide|dodeca-2E-ene-8,10-diynoic acid isobutylamide

(2E)-N-isobutyldodeca-2-ene-8,10-diynamide|(E)-N-isobutyl dodeca-2-ene-8,10-diynamide|(E)-N-isobutyldodeca-2-en-8,10-diynamide|(E)-N-isobutyldodeca-2-ene-8,10-diynamide|2-Methylpropylamide 鈥樎?E)-2-Dodecene-8,10-diynoic acid|Alk5|dodeca-2E-en-8,10-diynoic acid isobutylamide|dodeca-2E-ene-8,10-diynoic acid isobutylamide

C16H23NO (245.17795479999998)


   
   
   
   
   
   

Isovalerylcarnitine

isovaleryl-L-carnitine

C12H23NO4 (245.16269979999998)


An O-isovalerylcarnitine that is the 3-methylbutanoyl (isovaleryl) derivative of L-carnitine. Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis[1][2][3].

   

Leu-Gly-Gly

Leu-Gly-Gly

C10H19N3O4 (245.13754939999998)


A tripeptide composed of one L-leucine and two glycine residues joined in sequence. CONFIDENCE standard compound; INTERNAL_ID 164

   

Valeryl-carnitine; AIF; CE0; CorrDec

Valeryl-carnitine; AIF; CE0; CorrDec

C12H23NO4 (245.16269979999998)


   

Valeryl-carnitine; AIF; CE10; CorrDec

Valeryl-carnitine; AIF; CE10; CorrDec

C12H23NO4 (245.16269979999998)


   

Valeryl-carnitine; AIF; CE30; CorrDec

Valeryl-carnitine; AIF; CE30; CorrDec

C12H23NO4 (245.16269979999998)


   

Valeryl-carnitine; AIF; CE0; MS2Dec

Valeryl-carnitine; AIF; CE0; MS2Dec

C12H23NO4 (245.16269979999998)


   

Valeryl-carnitine; AIF; CE10; MS2Dec

Valeryl-carnitine; AIF; CE10; MS2Dec

C12H23NO4 (245.16269979999998)


   

Valeryl-carnitine; AIF; CE30; MS2Dec

Valeryl-carnitine; AIF; CE30; MS2Dec

C12H23NO4 (245.16269979999998)


   
   
   
   
   

(2S,5S)-5-((E)-pent-2-en-4-yn-1-yl)-2-propyldecahydroquinoline

(2S,5S)-5-((E)-pent-2-en-4-yn-1-yl)-2-propyldecahydroquinoline

C17H27N (245.2143382)


   

(5R,8R)-8-(but-3-en-1-yl)-5-(pent-4-yn-1-yl)octahydroindolizine

(5R,8R)-8-(but-3-en-1-yl)-5-(pent-4-yn-1-yl)octahydroindolizine

C17H27N (245.2143382)


   

(5S,8R)-8-ethyl-5-((E)-hept-1-en-6-yn-1-yl)octahydroindolizine

(5S,8R)-8-ethyl-5-((E)-hept-1-en-6-yn-1-yl)octahydroindolizine

C17H27N (245.2143382)


   

(E)-8-methyl-5-(oct-5-en-7-yn-1-yl)octahydroindolizine

(E)-8-methyl-5-(oct-5-en-7-yn-1-yl)octahydroindolizine

C17H27N (245.2143382)


   

(E)-8-ethyl-5-(hept-4-en-6-yn-1-yl)octahydroindolizine

(E)-8-ethyl-5-(hept-4-en-6-yn-1-yl)octahydroindolizine

C17H27N (245.2143382)


   

(5R,8R)-8-ethyl-5-(hept-6-yn-1-yl)-1,2,3,5,8,8a-hexahydroindolizine

(5R,8R)-8-ethyl-5-(hept-6-yn-1-yl)-1,2,3,5,8,8a-hexahydroindolizine

C17H27N (245.2143382)


   

(5R,8R)-8-(but-3-yn-1-yl)-5-pentyl-1,2,3,5,8,8a-hexahydroindolizine

(5R,8R)-8-(but-3-yn-1-yl)-5-pentyl-1,2,3,5,8,8a-hexahydroindolizine

C17H27N (245.2143382)


   

(E)-6-ethyl-5-(hex-3-en-5-yn-1-yl)-8-methyloctahydroindolizine

(E)-6-ethyl-5-(hex-3-en-5-yn-1-yl)-8-methyloctahydroindolizine

C17H27N (245.2143382)


   

(10S)-3,7,10-trimethyl-1,3a,4,8,9,9a,10,10a-octahydrocyclopenta[b]quinolizine-2-carbaldehyde

(10S)-3,7,10-trimethyl-1,3a,4,8,9,9a,10,10a-octahydrocyclopenta[b]quinolizine-2-carbaldehyde

C16H23NO (245.17795479999998)


   

DODEC-2-ENE-8,10-DIYNOIC ACID ISOBUTYLAMIDE

DODEC-2-ENE-8,10-DIYNOIC ACID ISOBUTYLAMIDE

C16H23NO (245.17795479999998)


   

Ala-arg

2-(2-amino-5-carbamimidamidopentanamido)propanoic acid

C9H19N5O3 (245.1487824)


   

Arg-ala

2-(2-aminopropanamido)-5-carbamimidamidopentanoic acid

C9H19N5O3 (245.1487824)


A dipeptide formed from L-arginyl and L-alanine residues.

   

Asn-Ile

2-(2-amino-3-methylpentanamido)-3-carbamoylpropanoic acid

C10H19N3O4 (245.13754939999998)


A dipeptide obtained by formal condensation of the carboxy group of L-asparagine with the amino group of L-isoleucine.

   

Asn-leu

2-(2-amino-4-methylpentanamido)-3-carbamoylpropanoic acid

C10H19N3O4 (245.13754939999998)


   

GLN-Val

2-(2-amino-3-methylbutanamido)-4-carbamoylbutanoic acid

C10H19N3O4 (245.13754939999998)


   

Ile-Asn

2-(2-amino-3-carbamoylpropanamido)-3-methylpentanoic acid

C10H19N3O4 (245.13754939999998)


A dipeptide formed from L-isoleucine and L-asparagine residues.

   

Leu-asn

2-(2-amino-3-carbamoylpropanamido)-4-methylpentanoic acid

C10H19N3O4 (245.13754939999998)


A dipeptide composed of L-leucine and L-asparagine joined by a peptide linkage.

   

Lys-val

6-amino-2-(2-amino-3-methylbutanamido)hexanoic acid

C11H23N3O3 (245.1739328)


A dipeptide formed from L-lysine and L-valine residues.

   

Val-Gln

2-(2-amino-4-carbamoylbutanamido)-3-methylbutanoic acid

C10H19N3O4 (245.13754939999998)


A dipeptide formed from L-valine and L-glutamine residues.

   

Val-lys

2-(2,6-diaminohexanamido)-3-methylbutanoic acid

C11H23N3O3 (245.1739328)


A dipeptide formed from L-valine and L-lysine residues.

   

Val-gglu

2-[2-amino-4-(C-hydroxycarbonimidoyl)butanamido]-3-methylbutanoic acid

C10H19N3O4 (245.13754939999998)


   

GGlu-Val

2-(2-amino-3-methylbutanamido)-4-(C-hydroxycarbonimidoyl)butanoic acid

C10H19N3O4 (245.13754939999998)


   

pivaloylcarnitine

3-[(2,2-dimethylpropanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO4 (245.16269979999998)


   

CAR 5:0

3-[(2,2-dimethylpropanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C12H23NO4 (245.16269979999998)


Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis[1][2][3].

   

NA 16:5

N-(2-Methylbutyl)-2E-undecene-8,10-diynamide

C16H23NO (245.17795479999998)


   
   

1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol

1-[Cyano-(p-methoxyphenyl)methyl]cyclohexanol

C15H19NO2 (245.1415714)


   

4-(TRANS-4-PROPYLCYCLOHEXYL)-2-FLUOROBENZONITRILE

4-(TRANS-4-PROPYLCYCLOHEXYL)-2-FLUOROBENZONITRILE

C16H20FN (245.1579692)


   

1-(1-BENZYLPYRROLIDIN-3-YL)-PIPERAZINE

1-(1-BENZYLPYRROLIDIN-3-YL)-PIPERAZINE

C15H23N3 (245.18918779999998)


   

3-tert-Butoxycarbonylamino-5-methyl-hexanoic acid

3-tert-Butoxycarbonylamino-5-methyl-hexanoic acid

C12H23NO4 (245.16269979999998)


   

(s)-tert-butyl 4-(2-hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate

(s)-tert-butyl 4-(2-hydroxyethyl)-2,2-dimethyloxazolidine-3-carboxylate

C12H23NO4 (245.16269979999998)


   

Gamfexine

Gamfexine

C17H27N (245.2143382)


C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

   

Inaperisone

1-(4-ethylphenyl)-2-methyl-3-pyrrolidin-1-ylpropan-1-one

C16H23NO (245.17795479999998)


C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant Inaperisone is a centrally acting muscle relaxant. Inaperisone can inhibit the micturition reflex by acting indirectly on GABAB receptors in the brainstem[1].

   
   

Gly-gly-ile

Glycylglycyl-l-isoleucine

C10H19N3O4 (245.13754939999998)


A tripeptide composed of glycine, glycine and L-isoleucine residues joined in sequence.

   

Gly-gly-leu

Gly-gly-leu

C10H19N3O4 (245.13754939999998)


A tripeptide composed of glycine, glycine and L-leucine residues joined in sequence.

   
   

2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile

2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinonitrile

C12H16BN3O2 (245.1335506)


   

Methyl (2S,3S)-3-[(tert-butyldimethylsilyl)oxy]azetidine-2-carbo

Methyl (2S,3S)-3-[(tert-butyldimethylsilyl)oxy]azetidine-2-carbo

C11H23NO3Si (245.14471279999998)


   

(R)-1-(1-benzylpyrrolidin-3-yl)piperazine

(R)-1-(1-benzylpyrrolidin-3-yl)piperazine

C15H23N3 (245.18918779999998)


   

(S)-1-(1-benzylpyrrolidin-3-yl)piperazine

(S)-1-(1-benzylpyrrolidin-3-yl)piperazine

C15H23N3 (245.18918779999998)


   
   

5-TERT-BUTYL-2-(2-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE

5-TERT-BUTYL-2-(2-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE

C14H19N3O (245.15280439999998)


   
   

2-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid

2-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid

C12H23NO4 (245.16269979999998)


   

4-(4-Pentylcyclohexyl)aniline

4-(4-Pentylcyclohexyl)aniline

C17H27N (245.2143382)


   

1-BOC-4-HYDROXYMETHYL-4-METHOXY-PIPERIDINE

1-BOC-4-HYDROXYMETHYL-4-METHOXY-PIPERIDINE

C12H23NO4 (245.16269979999998)


   

(R)-3-((tert-Butoxycarbonyl)amino)-5-methylhexanoic acid

(R)-3-((tert-Butoxycarbonyl)amino)-5-methylhexanoic acid

C12H23NO4 (245.16269979999998)


   

6-Amino-4-cyanopyridine-3-boronic acid pinacol ester

6-Amino-4-cyanopyridine-3-boronic acid pinacol ester

C12H16BN3O2 (245.1335506)


   

tert-butyl (2S,3R,4S)-4-hydroxy-2-(MethoxyMethyl)-3-Methylpyrrol

tert-butyl (2S,3R,4S)-4-hydroxy-2-(MethoxyMethyl)-3-Methylpyrrol

C12H23NO4 (245.16269979999998)


   

(S)-Tert-Butyl (1,5-diamino-1,5-dioxopentan-2-yl)carbamate

(S)-Tert-Butyl (1,5-diamino-1,5-dioxopentan-2-yl)carbamate

C10H19N3O4 (245.13754939999998)


   

3-butyl-1-ethyl-4-hydroxyquinolin-2-one

3-butyl-1-ethyl-4-hydroxyquinolin-2-one

C15H19NO2 (245.1415714)


   

N-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide

N-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetamide

C16H23NO (245.17795479999998)


   
   

3-(N-CYCLOHEXYLAMINO)PROPYLMETHYLDIMETHOXYSILANE

3-(N-CYCLOHEXYLAMINO)PROPYLMETHYLDIMETHOXYSILANE

C12H27NO2Si (245.1810962)


   

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride

4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride

C11H21BClNO2 (245.13537860000002)


   

5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine

5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine

C12H16BN3O2 (245.1335506)


   

3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine

3-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrimidine

C12H16BN3O2 (245.1335506)


   

3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine

3-(tert-Butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine

C14H19N3O (245.15280439999998)


   

1,3-DIBUTYL-1,1,3,3-TETRAMETHYLDISILAZANE

1,3-DIBUTYL-1,1,3,3-TETRAMETHYLDISILAZANE

C12H31NSi2 (245.19949259999999)


   

1-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)ETHAN-1-ONE OXIME

1-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YL)ETHAN-1-ONE OXIME

C16H23NO (245.17795479999998)


   

3-(TERT-BUTYL)-1-(4-METHOXYPHENYL)-1H-PYRAZOL-5-AMINE

3-(TERT-BUTYL)-1-(4-METHOXYPHENYL)-1H-PYRAZOL-5-AMINE

C14H19N3O (245.15280439999998)


   
   

oxolamine

oxolamine

C14H19N3O (245.15280439999998)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

   

1-(4-METHYLOXAZOL-5-YL)ETHANONE

1-(4-METHYLOXAZOL-5-YL)ETHANONE

C15H19NO2 (245.1415714)


   
   

6,7-dimethylspiro[3H-chromene-2,4-piperidine]-4-one

6,7-dimethylspiro[3H-chromene-2,4-piperidine]-4-one

C15H19NO2 (245.1415714)


   

4,4-Bis(hydroxymethyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester

4,4-Bis(hydroxymethyl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester

C12H23NO4 (245.16269979999998)


   
   

trans-2-(4-cyanophenyl)-5-n-butyl-1,3-dioxane

trans-2-(4-cyanophenyl)-5-n-butyl-1,3-dioxane

C15H19NO2 (245.1415714)


   
   

9-Benzyl-6-oxa-9-azaspiro[3.6]decan-8-one

9-Benzyl-6-oxa-9-azaspiro[3.6]decan-8-one

C15H19NO2 (245.1415714)


   
   

(S)-2-TERT-BUTOXYCARBONYLAMINO-HEPTANOICACID

(S)-2-TERT-BUTOXYCARBONYLAMINO-HEPTANOICACID

C12H23NO4 (245.16269979999998)


   
   

2-Propanol,1,1-iminobis[3-(2-propen-1-yloxy)-

2-Propanol,1,1-iminobis[3-(2-propen-1-yloxy)-

C12H23NO4 (245.16269979999998)


   

10-benzyl-5,8-dioxa-10-azadispiro[2.0.44.33]undecane

10-benzyl-5,8-dioxa-10-azadispiro[2.0.44.33]undecane

C15H19NO2 (245.1415714)


   

5-Allylpyridine-3-boronic acid pinacol ester

5-Allylpyridine-3-boronic acid pinacol ester

C14H20BNO2 (245.15870100000004)


   

(3,5-Ditert-butyl-4-hydroxyphenyl)acetonitrile

(3,5-Ditert-butyl-4-hydroxyphenyl)acetonitrile

C16H23NO (245.17795479999998)


   

(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)LITHIUM

(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)LITHIUM

C12H23NO4 (245.16269979999998)


   

8-Benzyl-1,3,8-triazaspiro[4.5]decane-4-one

8-Benzyl-1,3,8-triazaspiro[4.5]decane-4-one

C14H19N3O (245.15280439999998)


   

1,2-Ethanediamine,N1-(2-furanylmethyl)-N2,N2-dimethyl-N1-2-pyridinyl-

1,2-Ethanediamine,N1-(2-furanylmethyl)-N2,N2-dimethyl-N1-2-pyridinyl-

C14H19N3O (245.15280439999998)


   

ETHYL 3-BENZYL-3-AZA-BICYCLO[3.1.0]HEXANE-6-CARBOXYLATE

ETHYL 3-BENZYL-3-AZA-BICYCLO[3.1.0]HEXANE-6-CARBOXYLATE

C15H19NO2 (245.1415714)


   

6-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one

6-(4-methylpiperazin-1-yl)-3,4-dihydro-2H-isoquinolin-1-one

C14H19N3O (245.15280439999998)


   

5-tert-butyl-1H-indole-2-carboxylic acid ethyl ester

5-tert-butyl-1H-indole-2-carboxylic acid ethyl ester

C15H19NO2 (245.1415714)


   

H-Gly-Leu-Gly-OH

N-(N-Glycyl-L-leucyl)glycine

C10H19N3O4 (245.13754939999998)


   

(R)-3-METHYL-PYRROLIDINEHYDROCHLORIDE

(R)-3-METHYL-PYRROLIDINEHYDROCHLORIDE

C16H23NO (245.17795479999998)


   

3-((tert-Butoxycarbonyl)amino)-4,4-dimethylpentanoic acid

3-((tert-Butoxycarbonyl)amino)-4,4-dimethylpentanoic acid

C12H23NO4 (245.16269979999998)


   

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

C14H20BNO2 (245.15870100000004)


   

7-Benzyl-2-oxa-7-azaspiro[4.5]decan-1-one

7-Benzyl-2-oxa-7-azaspiro[4.5]decan-1-one

C15H19NO2 (245.1415714)


   

8-Benzyl-1-oxa-8-azaspiro[4.5]decan-2-one

8-Benzyl-1-oxa-8-azaspiro[4.5]decan-2-one

C15H19NO2 (245.1415714)


   

1-Oxa-9-azaspiro[5.5]undecane, 9-(phenylmethyl)-

1-Oxa-9-azaspiro[5.5]undecane, 9-(phenylmethyl)-

C16H23NO (245.17795479999998)


   

ethyl 3-(tert-butoxycarbonylamino)-3-Methylbutanoate

ethyl 3-(tert-butoxycarbonylamino)-3-Methylbutanoate

C12H23NO4 (245.16269979999998)


   

(R)-2-(((tert-Butoxycarbonyl)amino)methyl)-4-methylpentanoic acid

(R)-2-(((tert-Butoxycarbonyl)amino)methyl)-4-methylpentanoic acid

C12H23NO4 (245.16269979999998)


   

Methyl spiro[cyclohexane-1,3-indoline]-4-carboxylate

Methyl spiro[cyclohexane-1,3-indoline]-4-carboxylate

C15H19NO2 (245.1415714)


   

(3E)-1-(2,6-dimethylphenyl)-3-(1-methylpyrrolidin-2-ylidene)urea

(3E)-1-(2,6-dimethylphenyl)-3-(1-methylpyrrolidin-2-ylidene)urea

C14H19N3O (245.15280439999998)


   

trans-4-(5-Butyl-1,3-dioxane-2-yl)benzenenitril

trans-4-(5-Butyl-1,3-dioxane-2-yl)benzenenitril

C15H19NO2 (245.1415714)


   

undec-10-enoic acid, compound with 2-aminoethanol (1:1)

undec-10-enoic acid, compound with 2-aminoethanol (1:1)

C13H27NO3 (245.1990832)


   

1-Benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid

1-Benzyl-4-cyclopropyl-3-pyrrolidinecarboxylic acid

C15H19NO2 (245.1415714)


   
   
   

1-(Hydroxycyclohexyl)-(4-methoxyphenyl)acetonitrile

1-(Hydroxycyclohexyl)-(4-methoxyphenyl)acetonitrile

C15H19NO2 (245.1415714)


   

1H-Benzo[d][1,2,3]triazol-5-ylboronic acid pinacol ester

1H-Benzo[d][1,2,3]triazol-5-ylboronic acid pinacol ester

C12H16BN3O2 (245.1335506)


   

(S,S,S)-2-Azabicyclo[3,3,0]octane-3-carboxylic acid benzylester hydrochloride

(S,S,S)-2-Azabicyclo[3,3,0]octane-3-carboxylic acid benzylester hydrochloride

C15H19NO2 (245.1415714)


   

(n-(3-trifluoromethyl)benzenesulfonyl)alanine

(n-(3-trifluoromethyl)benzenesulfonyl)alanine

C12H27NO2Si (245.1810962)


   

Tasimelteon

Tasimelteon

C15H19NO2 (245.1415714)


N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CH - Melatonin receptor agonists C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant

   

2-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

2-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

C14H20BNO2 (245.15870100000004)


   
   

1-BENZYL-1,2,3,6-TETRAHYDROISONICOTINIC ACID ETHYL ESTER

1-BENZYL-1,2,3,6-TETRAHYDROISONICOTINIC ACID ETHYL ESTER

C15H19NO2 (245.1415714)


   
   

[2-(1-adamantyloxy)propyl]amine hydrochloride

[2-(1-adamantyloxy)propyl]amine hydrochloride

C13H24ClNO (245.15463239999997)


   

2-Amino-5-benzyl-3-methyl-5-propyl-3,5-dihydro-4H-imidazol-4-one

2-Amino-5-benzyl-3-methyl-5-propyl-3,5-dihydro-4H-imidazol-4-one

C14H19N3O (245.15280439999998)


   

2-Amino-5-butyl-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one

2-Amino-5-butyl-3-methyl-5-phenyl-3,5-dihydro-4H-imidazol-4-one

C14H19N3O (245.15280439999998)


   

N,N-dimethyl-4-(4-oxocyclohexyl)benzamide

N,N-dimethyl-4-(4-oxocyclohexyl)benzamide

C15H19NO2 (245.1415714)


   

Boc-Leu-OMe

Methyl N-(tert-butoxycarbonyl)-L-leucinate

C12H23NO4 (245.16269979999998)


   

Di-​tert-​butyl iminodiacetate

Di-​tert-​butyl iminodiacetate

C12H23NO4 (245.16269979999998)


   

[1,2,4]triazolo[1,5-a]pyridine-6-boronic acid pinacol ester

[1,2,4]triazolo[1,5-a]pyridine-6-boronic acid pinacol ester

C12H16BN3O2 (245.1335506)


   

8-Benzyl-1,3,8-triaza-spiro[4.5]decan-4-one

8-Benzyl-1,3,8-triaza-spiro[4.5]decan-4-one

C14H19N3O (245.15280439999998)


   

9-methoxy-3-methyl-9-phenyl-3-azabicyclo[3.3.1]nonane

9-methoxy-3-methyl-9-phenyl-3-azabicyclo[3.3.1]nonane

C16H23NO (245.17795479999998)


   

(R)-TERT-BUTYL 4-(2-HYDROXYETHYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE

(R)-TERT-BUTYL 4-(2-HYDROXYETHYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE

C12H23NO4 (245.16269979999998)


   

diallyl n,n-diisopropylphosphoramidite

diallyl n,n-diisopropylphosphoramidite

C12H24NO2P (245.15445739999998)


   

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

C13H19N5 (245.16403739999998)


   
   

N-(3-(5,6,7,8-Tetrahydro-2-naphthyl)prop-2-enyl)acetohydroxamic acid

N-(3-(5,6,7,8-Tetrahydro-2-naphthyl)prop-2-enyl)acetohydroxamic acid

C15H19NO2 (245.1415714)


   
   
   
   
   
   
   

4-(ethoxycarbonyl)-3,5-dimethyl-1-phenyl-1H-pyrazol-2-ium

4-(ethoxycarbonyl)-3,5-dimethyl-1-phenyl-1H-pyrazol-2-ium

C14H17N2O2+ (245.12899620000002)


   
   

2-(2,6-Diaminohexanoylamino)-3-methylbutanoic acid

2-(2,6-Diaminohexanoylamino)-3-methylbutanoic acid

C11H23N3O3 (245.1739328)


   

2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoic Acid

2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoic Acid

C9H19N5O3 (245.1487824)


   

Valerylcarnitine

Valerylcarnitine

C12H23NO4 (245.16269979999998)


Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines.

   
   
   
   
   

N3-decanoyl-N3-hydroxy-1,3-diaminopropane

N3-decanoyl-N3-hydroxy-1,3-diaminopropane

C13H29N2O2+ (245.2228914)


   
   

O-valeroylcarnitine

O-valeroylcarnitine

C12H23NO4 (245.16269979999998)


A C5-acylcarnitine in which the acyl group specified is valeroyl.

   

2-Methylbutyrylcarnitine

2-Methylbutyrylcarnitine

C12H23NO4 (245.16269979999998)


A C5-acylcarnitine having 2-methylbutyryl as the acyl substituent.

   
   

4-(N-Maleimido)benzyltrimethylammonium

4-(N-Maleimido)benzyltrimethylammonium

C14H17N2O2+ (245.12899620000002)


   

O-pivaloylcarnitine

O-pivaloylcarnitine

C12H23NO4 (245.16269979999998)


A C5-acylcarnitine in which the acyl group specified is pivaloyl.

   

3-hydroxy-N-(1-hydroxy-3-methylpentan-2-yl)-5-oxohexanamide

3-hydroxy-N-(1-hydroxy-3-methylpentan-2-yl)-5-oxohexanamide

C12H23NO4 (245.16269979999998)


   
   

4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butanoic acid

4-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)butanoic acid

C15H19NO2 (245.1415714)


   

tert-butyl N-(4-hydroxyoctan-2-yl)carbamate

tert-butyl N-(4-hydroxyoctan-2-yl)carbamate

C13H27NO3 (245.1990832)


   

(2S)-(caprinylamino)(hydroxy)acetic acid

(2S)-(caprinylamino)(hydroxy)acetic acid

C12H23NO4 (245.16269979999998)


   

(3R)-3-pentanoyloxy-4-[tris(trideuteriomethyl)azaniumyl]butanoate

(3R)-3-pentanoyloxy-4-[tris(trideuteriomethyl)azaniumyl]butanoate

C12H23NO4 (245.16269979999998)


   

4-[3-(4-Aminobutylamino)propylamino]-4-oxobutanoic acid

4-[3-(4-Aminobutylamino)propylamino]-4-oxobutanoic acid

C11H23N3O3 (245.1739328)


   

(3R)-3-(carboxymethylamino)decanoic acid

(3R)-3-(carboxymethylamino)decanoic acid

C12H23NO4 (245.16269979999998)


   

(2S)-2-hydroxy-4-methyl-1-(1-methylindol-3-yl)pentan-3-one

(2S)-2-hydroxy-4-methyl-1-(1-methylindol-3-yl)pentan-3-one

C15H19NO2 (245.1415714)


   

4-[4-(3-Aminopropylamino)butylamino]-4-oxobutanoic acid

4-[4-(3-Aminopropylamino)butylamino]-4-oxobutanoic acid

C11H23N3O3 (245.1739328)


   
   

N-(4-Phenylbutyryl)piperidin-2-one

N-(4-Phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(1,3-dihydroxynonan-2-yl)butanamide

N-(1,3-dihydroxynonan-2-yl)butanamide

C13H27NO3 (245.1990832)


   

N-(1,3-dihydroxyoctan-2-yl)pentanamide

N-(1,3-dihydroxyoctan-2-yl)pentanamide

C13H27NO3 (245.1990832)


   

N-(1,3-dihydroxydecan-2-yl)propanamide

N-(1,3-dihydroxydecan-2-yl)propanamide

C13H27NO3 (245.1990832)


   

N-(1,3-dihydroxyundecan-2-yl)acetamide

N-(1,3-dihydroxyundecan-2-yl)acetamide

C13H27NO3 (245.1990832)


   

N-(4,4-Dideutero-4-phenylbutyryl)piperidin-2-one

N-(4,4-Dideutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(3,3-Dideutero-4-phenylbutyryl)piperidin-2-one

N-(3,3-Dideutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(2,2-Dideutero-4-phenylbutyryl)piperidin-2-one

N-(2,2-Dideutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(3,3,4,4-Tetradeutero-4-phenylbutyryl)piperidin-2-one

N-(3,3,4,4-Tetradeutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(2,2,3,3-Tetradeutero-4-phenylbutyryl)piperidin-2-one

N-(2,2,3,3-Tetradeutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(2,2,4,4-Tetradeutero-4-phenylbutyryl)piperidin-2-one

N-(2,2,4,4-Tetradeutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(2,2,3,3,4,4-Hexadeutero-4-phenylbutyryl)piperidin-2-one

N-(2,2,3,3,4,4-Hexadeutero-4-phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

3-Hexanoyl-5-phenyl-2-isoxazoline

3-Hexanoyl-5-phenyl-2-isoxazoline

C15H19NO2 (245.1415714)


   

N-(2-Adamantyl)-2-methylcyclohexanimine

N-(2-Adamantyl)-2-methylcyclohexanimine

C17H27N (245.2143382)


   

N-(1-Adamantyl)-2-methylcyclohexanimine

N-(1-Adamantyl)-2-methylcyclohexanimine

C17H27N (245.2143382)


   

1-(2-Phenylbutyryl)piperidin-2-one

1-(2-Phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

1-(3-Phenylbutyryl)piperidin-2-one

1-(3-Phenylbutyryl)piperidin-2-one

C15H19NO2 (245.1415714)


   

N-(2-Butenyl)-N-(1-phenylpropyl)propanamide

N-(2-Butenyl)-N-(1-phenylpropyl)propanamide

C16H23NO (245.17795479999998)


   

Methyl 5-ethyl-3-methyl-2-phenyl-1-pyrroline-4-carboxylate (3,4-trans-4,5-cis)

Methyl 5-ethyl-3-methyl-2-phenyl-1-pyrroline-4-carboxylate (3,4-trans-4,5-cis)

C15H19NO2 (245.1415714)


   

Methyl trans-5-ethyl-ref.-4-methyl-2-phenyl-1-pyrroline-4-carboxylate

Methyl trans-5-ethyl-ref.-4-methyl-2-phenyl-1-pyrroline-4-carboxylate

C15H19NO2 (245.1415714)


   

1-Cyclohexyl-2-methyl-4,5,6,7,8,9-hexahydrocycloocta(B)pyrrole

1-Cyclohexyl-2-methyl-4,5,6,7,8,9-hexahydrocycloocta(B)pyrrole

C17H27N (245.2143382)


   

15-Methylaminobicyclo(8.3.2)pentadeca-1(13),10(15),11-trien-14-one

15-Methylaminobicyclo(8.3.2)pentadeca-1(13),10(15),11-trien-14-one

C16H23NO (245.17795479999998)


   

dezocine

dezocine

C16H23NO (245.17795479999998)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics N - Nervous system > N02 - Analgesics > N02A - Opioids

   

beta-Alanyl-L-arginine

beta-Alanyl-L-arginine

C9H19N5O3 (245.1487824)


   
   
   

O-Valeroyl-L-carnitine

O-Valeroyl-L-carnitine

C12H23NO4 (245.16269979999998)


An O-acyl-L-carnitine in which the acyl group specified is valeroyl.

   

L-Arginine, L-alanyl-

L-Arginine, L-alanyl-

C9H19N5O3 (245.1487824)


   

S-3-oxodecanoyl cysteamine

S-3-oxodecanoyl cysteamine

C12H23NO2S (245.1449418)


   
   
   

(R)-2-methylbutyrylcarnitine

(R)-2-methylbutyrylcarnitine

C12H23NO4 (245.16269979999998)


An optically active form of O-2-methylbutyrylcarnitine having (R)-configuration.

   

(3S)-3-(pentanoyloxy)-4-(trimethylazaniumyl)butanoate

(3S)-3-(pentanoyloxy)-4-(trimethylazaniumyl)butanoate

C12H23NO4 (245.16269979999998)


   
   

O-isovalerylcarnitine

O-isovalerylcarnitine

C12H23NO4 (245.16269979999998)


A C5-acylcarnitine having isovaleryl as the acyl substituent.

   

Gly-Gly-Ile zwitterion

Gly-Gly-Ile zwitterion

C10H19N3O4 (245.13754939999998)


A tripeptide zwitterion resulting from the transfer of a proton from the carboxy group to the amino group of Gly-Gly-Ile. Major microspecies at pH 7.3.

   
   

alpha-Pyrrolidinoisohexaphenone

alpha-Pyrrolidinoisohexaphenone

C16H23NO (245.17795479999998)


   

1-(6-hydroxyhexyl)indole-3-carbaldehyde

1-(6-hydroxyhexyl)indole-3-carbaldehyde

C15H19NO2 (245.1415714)


   

n-(2-methylbutyl)undec-2-en-8,10-diynimidic acid

n-(2-methylbutyl)undec-2-en-8,10-diynimidic acid

C16H23NO (245.17795479999998)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]ethanimidic acid

n-[2-(2,2-dimethylchromen-6-yl)ethyl]ethanimidic acid

C15H19NO2 (245.1415714)


   

(1s,2r,3r,6r,7ar)-6-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

(1s,2r,3r,6r,7ar)-6-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

C12H23NO4 (245.16269979999998)


   

(1s,9r,10r)-9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),7-dien-6-imine

(1s,9r,10r)-9-butyl-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),7-dien-6-imine

C15H23N3 (245.18918779999998)


   

5-octyl-1,2,3,4-tetrahydroquinoline

5-octyl-1,2,3,4-tetrahydroquinoline

C17H27N (245.2143382)


   

(1s,2r,3r,5s,7ar)-5-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

(1s,2r,3r,5s,7ar)-5-[(3s)-3-hydroxybutyl]-3-(hydroxymethyl)-hexahydro-1h-pyrrolizine-1,2-diol

C12H23NO4 (245.16269979999998)


   

(1s,4s,10s,12r)-9-[(1e)-but-1-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-6-imine

(1s,4s,10s,12r)-9-[(1e)-but-1-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodec-8-en-6-imine

C15H23N3 (245.18918779999998)


   

(2e,4z,10z)-n-(2-methylpropyl)dodeca-2,4,10-trien-8-ynimidic acid

(2e,4z,10z)-n-(2-methylpropyl)dodeca-2,4,10-trien-8-ynimidic acid

C16H23NO (245.17795479999998)


   
   

(2r)-2-hydroxy-1-(1h-indol-3-yl)-4-methylhexan-3-one

(2r)-2-hydroxy-1-(1h-indol-3-yl)-4-methylhexan-3-one

C15H19NO2 (245.1415714)


   

n-(2-methylpropyl)dodeca-2,4,10-trien-8-ynimidic acid

n-(2-methylpropyl)dodeca-2,4,10-trien-8-ynimidic acid

C16H23NO (245.17795479999998)